Nature of Business and Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2022

Condensed Financial Information Disclosure [Abstract]

Schedule of Restatement Consolidated Statement of Operations

The effect of the change to the classification is as follows:

	Three Months Ended March 31, 2022
(in thousands)	As reported		Adjustment			As restated
OPERATING EXPENSES:
Research and development	$	8,012	$	19,269		$	27,281
General and administrative		29,024		(19,269	)		9,755
Total operating expenses	$	37,036	$	-		$	37,036

Schedule of Restatement Earnings Per Share Basic and Diluted

The effect of the change to calculation and presentation of net loss per share for the three months ended March 31, 2021, on the condensed consolidated statement of operations, as well as the disclosures in Note 14, is as follows:

(In thousands, except shares and per share data)	THREE MONTHS ENDED MARCH 31, 2021
	As reported			Adjustment		As restated
Net loss	$	(21,283	)	$	—	$	(21,283	)
Numerator:
Less: Accruals of dividends of preferred stock		(4,296	)		4,296		-
Net loss available to common stockholders	$	(25,579	)	$	4,296	$	(21,283	)
Denominator:
Weighted-average common stock outstanding		96,300,247			-		96,300,247
Net loss per share, basic and diluted	$	(0.27	)	$	0.05	$	(0.22	)